Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial

What Was Tested

Researchers studied Tirzepatide in this randomized controlled trial publication.

The researchers assessed insulin sensitivity and β-cell function in adults with obesity/overweight, without diabetes, treated with tirzepatide for 72 weeks.

Who Took Part

The abstract describes 2,539 participants taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

This post hoc analysis from the Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) trial investigated tirzepatide versus placebo in 2,539 participants with BMI ≥27 kg/m2 and either prediabetes or normoglycemia at baseline.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

Model-derived parameters of β-cell function and insulin sensitivity were assessed from oral glucose tolerance tests.

What Was Measured

The subject headings attached to it are Blood Glucose, Glucose Tolerance Test, Insulin Resistance, Insulin-Secreting Cells, Obesity, Overweight and Prediabetic State.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Tirzepatide in 2,539 participants.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (Diabetes care), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.